Bayer Charts a Perilous Course: Settlement Deadline, Production Threat, and a Pharma Lifeline
05.06.2026 - 15:57:32 | boerse-global.de
Bayer’s stock edged up 2.09% on Friday to €36.08, reclaiming its 200-day moving average at €35.80 in a session that captured the company’s split personality. On one side, a busy legal calendar is reaching a crescendo; on the other, a nascent pharma catalyst and solid operating performance are offering shareholders a sliver of hope. The tug-of-war has left the shares nursing a 5.12% loss since the start of the year, even as the longer-term picture shows a 37.26% gain over twelve months.
The most immediate flashpoint is the June 5 opt-out deadline for the $7.25 billion Roundup settlement. Bayer is counting on high participation to cap its exposure to the roughly 100,000 glyphosate-related cancer claims still outstanding. But the company is also playing hardball in the courtroom, seeking to move proceedings back to a federal district court in Missouri after plaintiffs’ lawyers tried to shift them to California, where a judge seen as hostile to Bayer presides. UBS analyst Matthew Weston, who reiterates a buy rating and a €52 price target, sees the recent legal filings as part of a more assertive strategy that could give Bayer greater control over the litigation wave.
CEO Bill Anderson has escalated the fight beyond the courts. He is now warning that without a durable legal solution, Bayer could halt all glyphosate production in the United States — a move that would roil American agriculture. The threat underscores how deeply the Monsanto legacy continues to dominate the agenda, even as the underlying business delivers. In the first quarter of 2026, earnings per share beat expectations, helped by robust licensing revenue in the Crop Science division and steady growth in Consumer Health. The company’s market capitalisation stands at roughly €33.5 billion, but free cash flow is being drained by settlement payouts, diverting money from research and future expansion.
Should investors sell immediately? Or is it worth buying Bayer?
Shareholder patience is wearing thin. Union Investment recently captured the mood, calling for margins over visions and earnings over promises. Yet management has ruled out a spin-off of the agribusiness unit, insisting it will resolve the legal knots within the existing structure while keeping “all options open” — a rhetorical balancing act that reveals the strategic bind.
Away from the courtroom, there is tangible progress in the pharma pipeline. At the ERA kidney congress in Glasgow, Bayer presented full results from the Phase III FIND-CKD study showing that Kerendia significantly reduced the risk of major renal and cardiovascular events in patients with chronic kidney disease without diabetes. If approved for that broader population, the drug’s addressable market would expand markedly. The US Food and Drug Administration is already reviewing Kerendia under an accelerated pathway for type-1 diabetes, adding another potential growth driver for a division that badly needs new blockbusters.
New finance chief Judith Hartmann took the helm on June 1, and the market is watching for signs of stricter capital discipline. Net debt still exceeds €32 billion, a heavy burden that limits strategic flexibility. The stock’s modest rally on Friday does little to change the underlying scepticism: on a monthly view, shares remain 6.33% in the red.
The next major inflection point comes before the end of June, when the US Supreme Court is expected to rule in the Durnell case. A decision in Bayer’s favour could, according to industry assessments, remove the legal foundation for up to 80% of remaining lawsuits. Until then, every tick of the clock tightens the tension — and Anderson’s production ultimatum may soon move from rhetorical brinkmanship to a very real contingency plan.
Ad
Bayer Stock: New Analysis - 5 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
